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1. Introduction
   Randomised controlled trials (RCTs), also referred to as 
randomised clinical trials, have been described as the gold standard 
and widely accepted as the best trial design for comparing two 
or more medical therapies or health care interventions[1,2]. This 
claim is however correct only if the trial is appropriately designed, 
conducted and reported[3]. RCTs offer solutions to some of the 
issues that have been raised against observational studies. For 
example, as earlier observed[4], treatment differences identified 
from observational designs, rather than from experimental clinical 
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trials are subject to methodological weaknesses, including selection 
bias, confounding and cohort effects-variations in characteristics 
of an area of study over time among individuals who are defined 
by some shared temporal experience, such as year of birth. 
Previous studies have reckoned, however, that a well conducted 
observational study can be more valuable than RCTs with 
distorted randomisation, as statistical considerations and overall 
interpretations usually take bias in non-experimental studies into 
account[5,6].
   Furthermore, distorted view in RCTs is not limited to allocation 
of participants; it is also a thing of concern in certain statistical 
procedures involved in the delivery of a meaningful RCT. Since 
the authenticity of RCTs depends largely on the correctness of 
the design, conduct and reporting, it is important to make clear 
concepts and current trends of procedures involved, especially 
those that have considerable statistical notions. For example, 
the way and manner of comparing treatment groups for their 
similarities in prognostic factors at baseline differ among clinical 
researchers. While some adopt a practice of using tests of 
significance by using P-values to measure baseline comparability 
between groups or justify their choice of covariates to adjust in 
the mainstream analysis, others renounce such practice and regard 
it as unnecessary. The aim of this paper is to clarify issues and 
present clear information regarding certain statistical concepts and 
procedures that are necessary for the delivery of meaningful RCTs. 
Previous studies have focused on selected aspects of the design 
of RCTs[7,8]. The simplest and perhaps the most popular type of 
clinical trial is the two-arm parallel design, in which the study 
participants on recruitment to the trial are randomised to either of 
the two treatment groups[1,9-12]. 
2. Method
   This is a narrative synthesis of concepts and acceptable practices 
of selected statistical issues in RCTs. Searches for literatures were 
conducted electronically and manually where necessary. In total, 
44 literatures including articles and books on the subjects were 
accessed from various sources: library text materials, PubMed 
bibliographic database and literature suggestions from friends and 
colleagues. Five statistical issues, namely, baseline comparability, 
selection of covariate for adjustment, covariate adjustment, 
intention-to-treat analysis (ITT) and subgroup analysis were 
considered in this paper.
3. Baseline comparability
   This is a single concept that has generated much controversy 
among trialists, statisticians, and clinical investigators who have 
the responsibility of measuring and interpreting treatment effects. 
Various authors have remarked that randomisation guarantees 
unbiased allocation of treatments to study participants and does not 
ensure for a particular trial that the patients or study participants 
in each treatment group will have similar characteristics[9,13]. 
This then suggests that randomisation, at best, secures unbiased 
treatment allocation, but not necessary balance. The view was 
shared by other researchers who also noted that the procedure 
provides foundation for statistical tests in practice[11]. Since in 
practice following randomisation, some important covariates may 
not be balanced between treatment groups especially when the 
sample size is small; it is therefore a usual practice in clinical 
trial experiments to present baseline information on prognostic 
factors[14-16]. The first part of the result section is often devoted 
to the tabular presentation of the baseline characteristics of the 
study participants. This practice allows for quick judgement of 
the success or otherwise of the randomisation procedure, and 
as a result, provides basic information on which confidence on 
subsequent treatment comparison hinges.  
   On the other hand, tests of significance that utilize P-value to 
determine the statistical significance of the observed baseline 
difference in patientsÊ characteristics are also being adopted. 
However, this practice has suffered wide criticism, and has been 
regarded as unnecessary. The consensus regarding baseline 
comparison of patientsÊ characteristics appears to be that 
researchers should present the distributions of such baseline 
information of treatment groups in a table, thus, allowing readers 
to see the extent of similarities of the groups[17,18]. Furthermore, 
this practice allows physicians to infer the results to particular 
patients[19]. Many authors disapprove of the use of hypothesis tests 
as means of comparing baseline characteristics across groups[20-
23]. They contest the practice whereby tests of significance used 
to assess comparability in respect of the magnitude of baseline 
imbalance. Their argument is that there is no need for such tests, as 
a proper randomisation procedure ensures that groupsÊ difference 
is entirely due to chance, and all such tests seek to establish is 
that the observed difference could or could not have been due to 
chance. They also argue that researchers who use hypothesis tests 
to compare baseline characteristics report fewer significant results 
than expected by chance, thus suspecting a foul play in reporting. 
The procedure of hypothesis tests on baseline characteristics has 
been described as not only clearly absurd but also as unnecessary 
and might also be harmful[16,20,22]. 
4. Selection of covariates for adjustment
   Irrespective of the method adopted at the design stage to bring 
about balance at baseline, the view shared by most clinical 
 Bolaji Emmanuel Egbewale /Asian Pac J Trop Biomed 2015; 5(5): 354-359
investigators (especially statisticians) is to further account for 
baseline imbalance by applying relevant statistical method. However, 
a major bone of contention is which covariate(s) to include in the 
statistical adjustment model. There are basically three different 
views on this issue of covariate selection for statistical adjustment. 
Perhaps the most popular one of these is the use of baseline tests of 
significance to determine which covariate to include in the model for 
adjustment. In this case, study groups are compared in a wide range 
of baseline variables; those with statistically significant difference 
between groups are automatically accounted for in the analysis, 
and those that are not significant are ignored[24]. It was observed 
by previous researchers that about 50% of clinical trial experiments 
published in four leading medical journals adopted this method[25]. 
However, this idea has suffered major set-back over the years, and its 
use has been greatly discouraged by methodologists[26]. 
   The basic argument against the afore-mentioned approach is that, 
since study participants are randomly allocated to treatment groups 
in the first instance, then, any observed difference must have been 
due to chance. It then appears absurd to again test whether the 
observed difference is purely by chance or not, which is what the 
test of significance does. In addition, ignoring baseline covariates 
that have prognostic influence but not significantly different between 
groups is also an argument against the correctness of the use of 
hypothesis testing approach for covariate selection[20-23,25,27,28]. In 
fact, as variously submitted, a significant imbalance will not matter 
if a factor does not predict outcome; whereas, a non-significant 
imbalance can benefit from covariate adjustment[25,28].
   The second view reflects the importance attached to the prognostic 
strength of covariates. However, there are two variants of this idea; 
the first bases the covariate prognostic importance on the level 
of correlation between the particular covariate and the outcome 
variable. The usual practice here is that, if there is a weak correlation, 
say, r  0.3, adjusting for the imbalance in such a covariate is not 
necessary even with a significant baseline difference in the covariate 
between the treatment groups. This appears to support the idea 
that non-significance does not matter if the covariate-outcome 
correlation is strong. Just like significance testing, examining 
strength of relationship between the baseline and the outcome 
variables is a data-driven procedure. Analysts should examine the 
correlation between the covariates and the outcome of interest 
before deciding on selection of such covariates for adjustment. A 
classic example is a trial of primary biliary cirrhosis that had a non-
significant baseline imbalance in a strong prognostic variable, serum 
bilirubin unadjusted, and adjusted analyses yielded P = 0.1 and P = 
0.02, respectively, for the treatment differences in survival[29]. This 
example touches on the importance of recognising the prognostic 
strength of baseline variables rather than the statistical significance 
of imbalances. 
   The third known principle that guide covariate selection for the 
purpose of adjustment of baseline imbalance appears to be a variant 
of the second with selection being on the basis of covariates that 
have been found a priori to be prognostic in relation to the outcome 
variable. This includes evidence of suitable covariate-outcome 
correlation (r ı 0.3) from previous research or pilot studies[16,27,28]. 
The decision on which covariate is selected for adjustment is taken 
before the trial starts and usually specified in the protocol. This 
agrees with the recommendation of the International Conference 
on Harmonization of Technical Requirements for Registration of 
Pharmaceuticals for human use guideline[11]. The idea of using 
covariates identified a priori would also cover statistically adjusting 
for stratification or minimisation factors.  
5. Covariate adjustment
   In practice, simple randomisation may not ensure balance in some 
important covariates. If any unbalanced covariates are strongly 
correlated with the study outcomes, their presence may make it 
difficult to interpret the results of statistical tests for the treatment 
effect[11]. Thus, it is important that such imbalances are corrected or 
adjusted. Other studies have recorded a beneficial effect of covariate 
adjustment over the unadjusted even for covariate with moderate 
correlation with the outcome variable[13,30]. The procedures for 
controlling the covariate imbalance can either be at the design stage 
or during statistical analysis; adjustment at the design stage includes 
the use of such techniques as minimisation and stratification. The 
procedure for adjustment during statistical analysis accounts for 
covariate imbalance at the analysis stage by using relevant statistical 
method appropriate for the purpose. 
   In the case of a single post treatment assessment of a continuous 
outcome variable, methods for adjustment at the statistical analysis 
stage are: change score analysis that determines group effect based 
on the difference between the baseline and the post treatment score 
(basic adjustment) and analysis of covariance, which is a model-
based adjustment that includes the baseline of the outcome variable 
in the model. Statistical adjustment can also be performed by the use 
of logistic regression or by pooling the stratified analyses, using, for 
example, a Mantel Haenszel test. In many clinical trials, both design 
methods that reduce covariates imbalance and statistical adjustment 
during analysis are used simultaneously. Previous researchers 
have observed that for a given set of covariates, even though the 
stratification or minimisation methods will make the treatment 
groups comparable in these variables[15], they do not completely 
remove the effect of imbalance. As a result, the stratification or 
minimisation factors need to be incorporated in the model for 
adjustment. Statistical adjustment can have a profound influence on 
effect estimates and tests of significance. For example, covariate-
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adjusted estimates are not only more precise than the unadjusted, but 
making the odds ratio or hazard ratio for logistic regression analyses 
and hazards models become further away from the null. Statistical 
adjustment for strong predictors of outcome achieves more valid 
treatment effect estimates and significance tests[25]. 
   In addition, with respect to chance imbalance between treatment 
groups in a baseline covariate (especially when the baseline 
covariates is strongly correlated with the outcome), an adjusted 
estimate of the treatment effect accounts for this observed imbalance 
while an unadjusted analyses does not[25,31]. A further benefit of 
the covariate adjusted analysis can be the creation of a predictive 
model which combines the influences of treatment and prognostic 
covariates in estimating the expected outcome for individual 
patients[31]. Moreover, the validity of an unadjusted analysis relies 
on the assumption that there are no important imbalances involving 
measured and unmeasured baseline covariates across treatment 
groups. When imbalances occur on measured predictors of outcome 
variables, adjusted analyses should be performed[32]. It should be 
added that even if the groups have similar characteristics, it might 
still be desirable to adjust for another variable if we know in advance 
that the variable is strongly related to prognosis. Although, a primary 
reason for adjustment for imbalance in one or more covariates is the 
removal of chance bias, adjusting for a prognostic variable may also 
lead to greater power of the trial[9,28,33].
6. ITT analysis
   ITT analysis is the strategy for the analysis of RCTs that compares 
patients in terms of the groups to which they were originally 
randomly assigned[34]. This implies that patients are always analysed 
in the group to which they were initially randomised even if they 
drop out of the study[34-36]. This principle is fundamental to the 
experimental nature of RCTs as it ensures that the ideal structure 
for comparison created by random assignment of participants into 
treatment group is not distorted. There is wide agreement that the 
most appropriate analysis set for the primary effectiveness analyses 
of any confirmatory (phase III) clinical trial is the ITT; this form of 
analysis assesses the overall clinical effectiveness most relevant to 
the real-life use of the therapy[12]. 
   It is a recommendation of the Consolidated Standard of Reporting 
Trials that authors should indicate whether analyses were performed 
on an ITT basis[37]. The only safe way to deal with all forms of 
protocol violation is to apply ITT; included here are patients who 
actually receive a treatment other than the one allocated, and patients 
who do not take their treatment (known as non-compliers). However, 
whether ITT principle also applies if it is discovered after the trial has 
begun that a patient was not eligible for the trial is opened to debate.  
   A different analysis strategy commonly used (as a secondary 
evaluation) is to exclude patients who have not adhered to the 
allocated management strategy for whatever reason. This form of 
analysis is called per-protocol analysis, efficacy analysis, explanatory 
analysis, or analysis by treatment administered. It only describes 
the outcomes of the participants who adhered to the research 
protocol. Previous study observe that per-protocol analysis becomes 
a problem especially when the reasons for non-adherence to the 
protocol are related to prognosis[38]. Empirical evidence suggests 
that participants who adhere tend to do better than those who do not 
adhere, even after adjustment for all known prognostic factors and 
irrespective of assignment to active treatment or placebo[39]. Thus, 
excluding non-compliers participants from the analysis leaves those 
who are destined to have a better outcome and destroys the unbiased 
comparison afforded by randomization. However, a relationship 
between a higher methodological quality of the trials and the 
reporting of the ITT has also been established[40].
7.  Subgroup analysis
   One of the reasons for collecting substantial baseline data from 
patients in a RCT is that subgroup analyses (treatment outcome 
comparisons for patients subdivided by baseline strata) may be 
carried out[25]. This is to assess whether treatment difference in 
outcome or lack of it depends on certain characteristics of patients. 
The results from such group-specific assessment can be used to 
generate hypothesis for future study[25,33]. Subgroup analyses are 
important if there are potentially large differences between stratified 
groups in the risk of a poor outcome with or without treatment, 
if there are practical questions about when to treat, or if there are 
doubts about benefit in specific groups such as elderly people which 
are leading to potentially inappropriate over- or under-treatment[41]. 
Since patients recruited into a clinical trial are not a homogeneous 
sample, their response to treatment and the differing impact on them 
of different treatments may well vary in ways that affect the choice 
of which treatment is best for which patients. It was argued that if 
in truth, there are specific subgroups of patients for which a new 
treatment is more or less effective or harmful than that is indicated 
by the overall comparison with standard treatment in the trial as a 
whole, there is a scientific and ethical obligation to try and identify 
such subgroups[31].     
   However, most trials only have sufficient statistical power to detect 
the overall main effect difference in response between treatment 
groups, so that if subgroup effects do exist, they may well go 
undetected because the trial was not large enough[8,31]. Smaller 
sample sizes within subgroups lead to greater standard errors and 
reduced power relative to the overall clinical trial, resulting in an 
increased risk of a false-negative result; whereas, the multiplicity 
of hypotheses tests that results from examining multiple subgroups 
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will lead to an increased risk of a false positive result: inflation 
of type I error[9]. The author further reckoned that to look for 
effects in subgroups is never a good way to rescue a study in 
which the primary ITT analysis fails to show an overall effect. 
The suggested approach to a sub-group analysis is to compare the 
difference between the treatments for the sub-groups of interest. 
The interaction can be examined within an appropriate multiple 
regression model, whether the outcome is continuous, binary or 
survival time. 
   The unadjusted strategy yields an average treatment effect 
without any consideration for heterogeneity in prognosis among 
patients. Although both covariate adjustment and subgroup analyses 
consider heterogeneity and attempt to provide more individualized 
estimates of treatment effect, they are substantially different[42]. 
The difference is that, while covariate adjustment obtains a single 
more individualised treatment effect estimate, which is assumed 
to be applicable to all patients[31,43], subgroup analyses provide 
multiple treatment effect estimates, assuming that treatment 
effects differ between particular groups of patients[44]. For the 
reason aforementioned, though subgroup analyses are sometimes 
performed, they rarely have enough power to detect differential 
treatment effect. It has however been variously observed that tests 
of interaction are underused and subgroup analyses are commonly 
over-interpreted[9,43]. Researchers should therefore be wary of this.
 
8. Conclusions
   In trial settings, it is no longer popular to use test of significance 
to assess baseline comparability of characteristics of study 
participants between treatment groups. It is sufficient to present 
distributions of baseline characteristics of treatment groups in 
a table, by so doing, readers are allowed to see the extent of 
similarities in the groups. Similarly, the practice of using tests of 
significant or P-value to determine which covariate(s) qualify for 
statistical adjustment is prone to yielding misleading results and 
have also been discouraged. A more rather acceptable approach 
will make use of the information on the extent of correlation 
between the covariate and the outcome variable. Usually, a 
covariate may qualify for statistical adjustment if its correlation 
with the outcome variable is greater than or equal to 0.3. 
   Furthermore, it should be noted that no design methods 
completely remove the effect of imbalance, therefore, stratification 
or minimisation factors should always be considered for inclusion 
in the statistical model for adjustment. Whenever protocol violation 
is observed, the only safe statistical approach that will help in 
dealing with it is ITT. By so doing, the experimental nature of RCTs 
which allows unbiased comparison of groupsÊ treatment effect 
is preserved. Researchers are required to report whether primary 
analyses were performed on an ITT basis or not. Lastly, subgroup 
analysis is essential especially when there is a huge difference in 
the observed treatment effect within identified groups in the trial 
participants. However, since the trial is only powered to detect a 
main effect, even if subgroup effect exists, they may as well pass 
unnoticed. A major use of results from subgroup analysis is to 
generate hypothesis for future clinical trials. Since RCTs are gold 
standard in the comparison of medical interventions, researchers 
cannot afford distorted allocation or statistical procedures in this 
all important experimental design method.  
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